Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine

Luisa Rossi, Rosanna Squitti, Patrizio Pasqualetti, Eliana Marchese, Emanuele Cassetta, Elisabetta Forastiere, Giuseppe Rotilio, Paolo M. Rossini, Alessandro Finazzi-Agró

Research output: Contribution to journalArticlepeer-review

Abstract

Copper, zinc superoxide dismutase (Cu, Zn SOD) activity was measured in red blood cells (RBC) of 32 patients affected by Alzheimer's disease (AD), eight other AD patients treated with the copper-chelating agent D-penicillamine, 13 first-degree relatives and 22 controls. All AD patients enrolled in our study showed a higher level of Cu, Zn SOD activity early in the disease. No correlation between apolipoprotein E genotype and SOD activity was found in AD patients. D-penicillamine treatment of AD patients for 24 weeks lowered the enzyme activity even below the control value. These results support the hypothesis that a higher level of Cu, Zn SOD activity in RBC can be an early diagnostic peripheral marker of this disease and a sensor to monitor treatments with copper-chelating drugs.

Original languageEnglish
Pages (from-to)137-140
Number of pages4
JournalNeuroscience Letters
Volume329
Issue number2
DOIs
Publication statusPublished - Aug 30 2002

Keywords

  • Alzheimer's disease
  • Apolipoprotein E
  • Copper
  • Copper, zinc superoxide dismutase
  • D-penicillamine

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Red blood cell copper, zinc superoxide dismutase activity is higher in Alzheimer's disease and is decreased by D-penicillamine'. Together they form a unique fingerprint.

Cite this